Skip to main content
Fig. 3 | Cell Communication and Signaling

Fig. 3

From: Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies

Fig. 3

The mechanism of action of anti-PD-1/PD-L1 drugs and the potential mechanism underlying the exosomal PD-L1-mediated resistance to anti-PD-L1 drugs. â‘  Anti-PD-1/PD-L1 drugs can interact with PD-1/PD-L1, free T cells from the checkpoint block, and restore immune responses. â‘¡ and â‘¢ Exo-PD-L1 is thought to contribute to resistance during immunotherapy through two mechanisms. In one, exo-PD-L1 binds to anti-PD-L1 monoclonal antibody (mAb), leading to PD-L1 exposure on the tumor surface (â‘¡); in the other, Although anti-PD-L1 mAb can interact with PD-L1 on the surface of tumor, exo-PD-L1 can directly interact with PD-1 on the surface of T cells to inhibit immunity (â‘¢)

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X